keyword
MENU ▼
Read by QxMD icon Read
search

Sezary

keyword
https://www.readbyqxmd.com/read/28423383/remarkable-advances-in-the-management-of-mycosis-fungoides-and-the-sezary-syndrome
#1
Richard T Hoppe
No abstract text is available yet for this article.
April 20, 2017: Oncology Research and Treatment
https://www.readbyqxmd.com/read/28408397/the-il-31-il-31-receptor-axis-general-features-and-role-in-tumor-microenvironment
#2
REVIEW
Elisa Ferretti, Anna Corcione, Vito Pistoia
IL-31 is a recently identified cytokine with a well-defined role in the pathogenesis of pruritus. IL-31, whose production is induced by IL-4 and IL-33, binds a heterodimeric receptor (R) composed of the exclusive IL-31RA chain and the shared oncostatin M R. Signaling through the IL-31R involves the MAPK, PI3K/AKT and Jak/STAT pathways. Different variants and isoforms of IL-31RA with different signaling activities have been identified. IL-31 is produced predominantly by circulating Th2 lymphocytes and skin-homing CLA(+)CD45RO(+) T cells...
April 13, 2017: Journal of Leukocyte Biology
https://www.readbyqxmd.com/read/28400642/cd3-cd56-cd4-cd8-cd20-cd30-peripheral-t-cell-non-hodgkin-s-lymphoma-a-rare-case-report
#3
Ashish Jagati, Bela J Shah, Sonal Tibrewal, Trusha Gajjar
Cutaneous T-cell lymphoma (CTCL) commonly presents as mycosis fungoides or Sezary syndrome, both having CD4 positivity. A subset of CTCL which lacks CD4 surface marker is classified as cutaneous γ and δ-T-cell lymphoma (CGD-TCL). Because of its rarity and inability to study large number of patients, the impact of immunophenotype on the clinical outcome of primary CTCL in patients is limited. We report a case of primary CGD-TCL in a 71-year-old male because of this rarity and to emphasize its aggressive nature...
March 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28400635/oral-and-cutaneous-lymphomas-other-than-mycosis-fungoides-and-s%C3%A3-zary-syndrome-in-a-mexican-cohort-recategorization-and-evaluation-of-international-geographical-disparities
#4
Amparo Hernández-Salazar, Jorge Andrés García-Vera, Yann Charli-Joseph, Guadalupe Ortiz-Pedroza, Silvia Méndez-Flores, Rocío Orozco-Topete, Ana Lilia Morales-Leyte, Judith Domínguez-Cherit, Carmen Lome-Maldonado
BACKGROUND: Nonmycosis fungoides/Sézary syndrome (non-MF/SS) primary cutaneous lymphomas (PCL) are currently categorized under the 2005-World Health Organization/European Organization for Research and Treatment of Cancer (WHO-EORTC) classification for PCL. These differ in behavior from secondary cutaneous lymphomas (SCL) and to lymphomas limited to the oral cavity (primary oral lymphomas [POL]) both categorized under the 2016-WHO classification for lymphoid neoplasms. AIMS: This study aims to report the first series of non-MF/SS PCL, SCL, and POL in a Mexican cohort, examine the applicability of current classification systems and compare our findings with those from foreign cohorts...
March 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28400633/new-targeted-treatments-for-cutaneous-t-cell-lymphomas
#5
Martine Bagot
Cutaneous T-cell lymphomas (CTCLs) represent a group of rare and heterogeneous diseases that are very difficult to treat at advanced stages. The development of monoclonal antibodies is a new hope for the treatment of these diseases. Alemtuzumab (Campath) is a humanized IgG1 kappa monoclonal antibody specific for CD52, an antigen expressed by most T and B lymphocytes. Alemtuzumab may frequently induce long-term remissions in patients with Sezary syndrome but high-dose treatments lead to severe cytopenia, immune depletion, and opportunistic infections...
March 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28391645/hematopoietic-stem-cell-transplantation-in-advanced-cutaneous-t-cell-lymphoma
#6
Hiroshi Saruta, Chika Ohata, Ikko Muto, Taichi Imamura, Eijiro Oku, Koichi Ohshima, Koji Nagafuji, Takekuni Nakama
We retrospectively reviewed data pertaining to five patients with cutaneous T-cell lymphoma (CTCL) who had received hematopoietic stem cell transplantation (HSCT) between 2004 and 2015 at Kurume University Hospital, along with their clinical data until March 2016. For patients with advanced CTCL eligible for HSCT, autologous HSCT was performed when they responded well to chemotherapy, and allogeneic HSCT was selected for patients with advanced mycosis fungoides (MF)/Sézary syndrome (SS) and CTCL other than MF/SS with poor chemosensitivity...
April 9, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28365528/european-organisation-for-research-and-treatment-of-cancer-consensus-recommendations-for-the-treatment-of-mycosis-fungoides-s%C3%A3-zary-syndrome-update-2017
#7
REVIEW
Franz Trautinger, Johanna Eder, Chalid Assaf, Martine Bagot, Antonio Cozzio, Reinhard Dummer, Robert Gniadecki, Claus-Detlev Klemke, Pablo L Ortiz-Romero, Evangelia Papadavid, Nicola Pimpinelli, Pietro Quaglino, Annamari Ranki, Julia Scarisbrick, Rudolf Stadler, Liisa Väkevä, Maarten H Vermeer, Sean Whittaker, Rein Willemze, Robert Knobler
In order to provide a common standard for the treatment of mycosis fungoides (MF) and Sézary syndrome (SS), the European Organisation for Research and Treatment of Cancer-Cutaneous Lymphoma Task Force (EORTC-CLTF) published in 2006 its consensus recommendations for the stage-adapted selection of management options for these neoplasms. Since then, the understanding of the pathophysiology and epidemiology of MF/SS has advanced, the staging system has been revised, new outcome data have been published and novel treatment options have been introduced...
March 30, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28355426/focal-pegylated-liposomal-doxorubicin-induced-urticarialike-reaction-at-cutaneous-transformed-s%C3%A3-zary-lesions
#8
Roger Haber, Caroline Ram-Wolff, Pauline Laly, Martine Bagot
No abstract text is available yet for this article.
March 29, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28340880/mycosis-fungoides-and-sezary-syndrome
#9
REVIEW
Francine M Foss, Michael Girardi
Mycosis fungoides and the Sezary syndrome (SS) are rare lymphomas of CD4(+) helper T cells. There is stagewise progression from patch/plaques to thicker tumor lesions/diffuse erythroderma. Blood involvement is a characteristic of SS. Outcomes are related to the extent of skin, blood, lymph node, and visceral organ involvement. Patients with limited patch and plaque disease are treated with skin-directed therapies. More advanced/refractory disease is treated with skin-directed therapies and oral or systemic immunomodulatory agents...
April 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28338261/extracorporeal-photopheresis-for-the-treatment-of-early-stage-mycosis-fungoides
#10
Daniel J Lewis, Madeleine Duvic
Extracorporeal photopheresis (ECP) has been used for nearly 30 years in the treatment of cutaneous T-cell lymphoma. However, current clinical practice largely reserves ECP for patients with late-stage mycosis fungoides (MF) or Sézary syndrome or for those who are refractory to other therapies. We briefly describe a 48-year-old male who experienced long-term complete remission of his patch MF disease with ECP, and we suggest a role for ECP in the treatment of early-stage MF given evidence of its efficacy, safety, and tolerability...
March 24, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28325251/interferon-induced-thrombotic-microangiopathy-tma-analysis-and-concise-review
#11
REVIEW
Ajay Kundra, Jen Chin Wang
Interferon (IFN) has been associated with development of thrombotic microangiopathy including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). We reviewed literature from the earliest reported association in 1993, to July 2016 and found 68 cases. Analysis of this data shows: (1) Mean age at diagnosis was 47 years (95% CI, 44-50). (2) Majority of cases were seen where IFN was used for the treatment of chronic myelogenous leukemia (CML), multiple sclerosis (MS), chronic hepatitis C virus infection (HCV) and one case each for hairy cell leukemia (HCL) and Sezary syndrome...
April 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28301507/tp53-alterations-in-primary-and-secondary-s%C3%A3-zary-syndrome-a-diagnostic-tool-for-the-assessment-of-malignancy-in-patients-with-erythroderma
#12
Audrey Gros, Elodie Laharanne, Marie Vergier, Martina Prochazkova-Carlotti, Anne Pham-Ledard, Thomas Bandres, Sandrine Poglio, Sabine Berhouet, Béatrice Vergier, Jean-Philippe Vial, Edith Chevret, Marie Beylot-Barry, Jean-Philippe Merlio
Recent massive parallel sequencing data have evidenced the genetic diversity and complexity of Sézary syndrome mutational landscape with TP53 alterations being the most prevalent genetic abnormality. We analyzed a cohort of 35 patients with SS and a control group of 8 patients with chronic inflammatory dermatoses. TP53 status was analyzed at different clinical stages especially in 9 patients with a past-history of mycosis fungoides (MF), coined secondary SS. TP53 mutations were only detected in 10 patients with either primary or secondary SS (29%) corresponding to point mutations, small insertions and deletions which were unique in each case...
2017: PloS One
https://www.readbyqxmd.com/read/28296250/different-genetic-alteration-of-a20-in-a-s%C3%A3-zary-syndrome-case-with-v%C3%AE-2-j%C3%AE-22-t-cell-clone
#13
Lingling Zhou, Haitao Zheng, Xin Huang, Lihua Zhu, Suijing Wu, Chengwu Zeng, Lijian Yang, Shaohua Chen, Gengxin Luo, Xin Du, Yangqiu Li
BACKGROUND: The comprehensive genetic alterations underlying the pathogenesis of Sézary syndrome (SS) remains largely unknown. Previous studies showed that alterations of tumor necrosis factor-α-induced protein 3 gene (TNFAIP3; A20) are frequent in SS. In this study, we characterized the mutation and polymorphisms of A20 in a case with SS and compared with the genetic feature of A20 in T-cell acute lymphoblastic leukemia (T-ALL). METHODS: Using a novel approach based on the combination of fine-tiling array comparative genomic hybridization ( and ligation-mediated polymerase chain reaction (LM-PCR) to identify SS clone, the polymorphisms in the A20 gene (promoter, exons 2-9 [coding region] and 3'UTR) were detected by PCR and sequencing...
March 14, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28271282/characterization-of-the-peripheral-neuropathy-associated-with-brentuximab-vedotin-treatment-of-mycosis-fungoides-and-s%C3%A3-zary-syndrome
#14
Zachary A Corbin, Annie Nguyen-Lin, Shufeng Li, Ziba Rahbar, Mahkam Tavallaee, Hannes Vogel, Katrin A Salva, Gary S Wood, Youn H Kim, Seema Nagpal
Chemotherapy-induced peripheral neuropathy (CIPN) is common, frequently limits chemotherapy dosing, and negatively impacts quality of life. The National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0, and the Total Neuropathy Score clinical version (TNSc) are both validated scores to quantify peripheral neuropathy (PN), with the TNSc being more sensitive to clinical changes. Mycosis fungoides and Sézary syndrome (MF/SS) are characterized by a chronic course, where current therapies are generally non-curative and treatment toxicities have the potential for significant lasting effects...
March 7, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28256712/the-oncogenic-role-of-mir-155-in-mycosis-fungoides-an-in-vitro-and-xenograft-mouse-model-study
#15
L Moyal, S Yehezkel, B Gorovitz, A Keren, A Gilhar, I Lubin, S Sherman, E Hodak
BACKGROUND: miR-155 contributes to the proliferation of mycosis fungoides (MF) in vitro and is upregulated in tumours of MF compared to early MF lesions. OBJECTIVES: To investigate the contribution of miR-155 to the cancerous phenotype and drug resistance of MF/Sezary cell lines. METHODS: miR-155 was inhibited in MF cell lines (MyLa and MJ) by transduction of miRZip anti-miR-155 and overexpressed in Hut78 cells by transduction of miRVec-miR-155; empty plasmids served as a control...
March 3, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28133821/total-skin-electron-therapy-as-treatment-for-epitheliotropic-lymphoma-in-a-dog
#16
Domenico Santoro, Lyndsay Kubicek, Bo Lu, William Craft, Julia Conway
BACKGROUND: Mycosis fungoides (MF) is an uncommon cutaneous neoplasm in dogs. Treatment options are limited. Total skin electron therapy (TSET) has been suggested as a possible therapy for canine MF. OBJECTIVE: To describe the use of TSET as palliative treatment for MF in a dog. RESULTS: An adult dog, previously diagnosed with nonepidermolytic ichthyosis, was presented with generalized erythroderma, alopecia and erosions. Histopathology revealed a densely cellular, well-demarcated, unencapsulated infiltrate extending from the epidermis to the mid-dermis compatible with MF...
January 29, 2017: Veterinary Dermatology
https://www.readbyqxmd.com/read/28119365/usefulness-of-kir3dl2-to-diagnose-follow-up-and-manage-the-treatment-of-s%C3%A3-zary-syndrome-patients
#17
Charlotte Hurabielle, Nicolas Thonnart, Caroline Ram-Wolff, Helene Sicard, Armand Bensussan, Martine Bagot, Anne Marie-Cardine
PURPOSE: KIR3DL2 is a recently discovered marker of the malignant clonal cell population in Sézary Syndrome (SS). We intended to evaluate the expression of KIR3DL2 on blood T-cells as a diagnostic, prognostic and follow-up marker of SS. EXPERIMENTAL DESIGN: 64 patients diagnosed with SS were included in this monocentric study. We collected the percentage of KIR3DL2+ cells among CD3+ T-cells, obtained by flow cytometry, and other classical diagnostic criteria for SS at diagnosis and during the follow-up...
January 24, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28107479/apoptosis-induction-and-gene-expression-profile-alterations-of-cutaneous-t-cell-lymphoma-cells-following-their-exposure-to-bortezomib-and-methotrexate
#18
Vassiliki Mpakou, Evangelia Papadavid, Frieda Kontsioti, Eugene Konsta, Miriam Vikentiou, Aris Spathis, Sotiris Papageorgiou, Diamantina Vasilatou, Konstantinos Gkontopoulos, Efthimia Mpazani, Petros Karakitsos, Dimitrios Rigopoulos, George Dimitriadis, Vasiliki Pappa
Mycosis fungoides (MF) and its leukemic variant Sézary syndrome (SS) comprise the majority of CTCL, a heterogenous group of non-Hodgkins lymphomas involving the skin. The CTCL's resistance to chemotherapy and the lack of full understanding of their pathogenesis request further investigation. With the view of a more targeted therapy, we evaluated in vitro the effectiveness of bortezomib and methotrexate, as well as their combination in CTCL cell lines, regarding apoptosis induction. Our data are of clinical value and indicate that the bortezomib/methotrexate combinational therapy has an inferior impact on the apoptosis of CTCL compared to monotherapy, with bortezomib presenting as the most efficient treatment option for SS and methotrexate for MF...
2017: PloS One
https://www.readbyqxmd.com/read/28034470/-cutaneous-granular-bacteriosis-occurring-in-staphylococcus-aureus-septicaemia
#19
D Mermin, A-L Védie, M-L Jullie, A Fauconneau, M Beylot-Barry, A Pham-Ledard
BACKGROUND: Herein we report a case of cutaneous granular bacteriosis, with discussion of the nosological setting of this entity based upon the clinical and histological findings. PATIENTS AND METHODS: A 62-year-old woman receiving methotrexate for Sezary syndrome was admitted for fever of 38.5̊C and overall impairment of her health. She presented a fistulous nodule on her right knee, and skin biopsy revealed a focus of ulcerated suppuration with quantities of Gram+ and Grocott+ granules containing no filament, enclosed by eosinophilic matter (Splendore-Hoeppli phenomenon)...
December 26, 2016: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28024703/a-new-molecular-paradigm-in-mycosis-fungoides-and-s%C3%A3-zary-syndrome
#20
Kojo S J Elenitoba-Johnson, Ryan Wilcox
Mycosis Fungoides (MF) and Sézary Syndrome (SS) are clonal proliferations of mature T-cells manifesting as lymphoproliferative disorders in which the neoplastic cells show a strong propensity for skin-homing. While the predominant site of presentation in MF is the skin, the peripheral blood carries a significant tumor burden in Sézary Syndrome such that it resembles a "leukemic" disease. While the genetic basis of these diseases has been studied using different approaches in the previous years, recent genome-wide studies employing massively parallel sequencing techniques now offer new insights into the molecular pathogenesis of these diseases...
January 2017: Seminars in Diagnostic Pathology
keyword
keyword
17270
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"